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We look back on the discoveries that the tyrosine kinases TYK2 and JAK1 and the transcription factors
STAT1, STAT2, and IRF9 are required for the cellular response to type I interferons. This initial description
of the JAK-STAT pathway led quickly to additional discoveries that type II interferons and many other cyto-
kines signal through similar mechanisms. This well-understood pathway now serves as a paradigm showing
how information from protein-protein contacts at the cell surface can be conveyed directly to genes in the
nucleus. We also review recent work on the STAT proteins showing the importance of several different post-
translational modifications, including serine phosphorylation, acetylation, methylation, and sumoylation.
These remarkably proficient proteins also provide noncanonical functions in transcriptional regulation and
they also function in mitochondrial respiration and chromatin organization in ways that may not involve
transcription at all.Scientists who have followed the development of the signal
transduction field over the past 30 years are likely to be aware
that the two authors of this Perspective have had a close working
relationship (ten joint papers published during the 1990s) as well
as a warm friendship, especially as the understanding of the JAK
(Janus kinase)-STAT (signal transducers and activators of tran-
scription) pathway emerged. However, we each came to the
study of the action of interferons (IFNs), the subject that uncov-
ered the JAK-STAT pathway, in our separate ways. Furthermore,
during the 1980s we were both studying gene induction by IFNs
with sometimes parallel and other times quite divergent aims.
We did frequently and freely discuss our plans and aims during
these years, which were obviously sometimes almost identical.
But by the late 1980s, our labs were emphasizing different
immediate goals. Experiments in the Darnell lab featured the
purification of site-specific, presumably regulatory DNA binding
proteins that finally unearthed the STAT family. The Stark group,
working closely in association with the group of Ian Kerr at the
Imperial Cancer Research Fund in London, turned in the late
1980s to genetics of human cells in culture, with the ultimate
goal of identifying all the major components of IFN-dependent
signaling. In particular, Sandra Pellegrini, a postdoctoral fellow,
developed a method to select mutant cell lines, followed by
complementation (by cellular fusion) that allowed identification
of eight different noncomplementing mutant cell lines, each of
which was no longer capable of responding to IFN-a and IFN-b
(IFN-I), IFN-g, or both. Molecular complementation of these
mutants uncovered the role of the JAKs in STAT activation and
later also proved the steps in STAT activation and the imputed
role of the STATs in IFN-I- and IFN-g-dependent transcriptional
activity.
In this Perspective, we each wish to speak in our own voices
about how the early discoveries (1984–1994) came about
(Table 1). Our separate historical sections are indicated. We
then reunite to describe the completion of the catalog of all the
JAKs and STATs, followed by an outline of the basic diagram
of JAK-STAT functions, many accomplished by joint efforts
with the mutant cell lines mentioned above. A final sectionfeatures important recently recognized aspects of STAT function
not covered in other reviews in this issue.
The Discovery of Interferon
The story of the JAK-STAT pathway begins with IFN. In 1957,
Alick Isaacs and Jean Lindenmann reported on a phenomenon
in the field of ‘‘virus interference,’’ generally used at the time to
describe conditions that disrupted virus formation (Isaacs and
Lindenmann, 1957; Isaacs et al., 1957). In a little-noticed paper
published in French, Nagano and Kokima (1954) had reported
earlier that rabbits injected in the skin with vaccinia virus devel-
oped a viral inhibitory factor after 5–7 hr that was insensitive to
ultraviolet radiation and of relatively small size as determined
by skin biopsies (not sedimented in the ultracentrifuge). How-
ever, it was not even clear that the infected cells secreted this
material. Isaacs and Lindenmann found that influenza virus-
infected chick embryo cells produced and released something
in the surrounding fluid that would instigate resistance to infec-
tion of noninfected cells. They showed that this material was
not, so far as they could determine, a ‘‘piece’’ of the originally in-
fecting virus, but was a product released continually for many
hours that in turn took a few hours to effect its protection on
newly exposed cells. Their tests on its chemical properties and
the relative size of the protective product suggested that it was
likely to be a small protein, which they named ‘‘interferon.’’ As
noted, the original experiments involved chicken embryo cells
and influenza virus, but the interferon preparations were also
capable of blocking the replication of several other RNA viruses,
including Sendai virus and Newcastle disease virus and also
vaccinia virus, a DNA virus. The Isaacs and Lindenmann discov-
eries revealed two remarkable broad conclusions. First, at the
potentially practical level, an ‘‘innate’’ host defense system
exists, triggered by virus infection, that causes infected cells to
produce a substance that can protect cells not yet infected
without waiting for antibody production. Second, at the basic
level, a secreted, (probably) protein product can profoundly alter
within a few hours the fundamental properties of the treated
cells. This very important original work was the beginning ofImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 503
Table 1. Sequence of the Discoveries that Have Revealed the JAK-STAT Pathways
Year Milestone
1957 Isaacs and Lindenmann describe interferon
1975–1977 Oligonucleotide [20-50 oligoadenylates(s)] inhibitors of protein synthesis induced by IFN found
1979 Actinomycin-sensitive IFN-b-dependent new protein induction shown
1984 IFN-a-induced transcriptional stimulation of specific genes (ISGs) demonstrated; no new protein synthesis required
1986–1988 IFN-dependent promoters identified (ISREs, interferon-stimulated response elements)
1988–1989 IFN-a-induced ISRE binding protein complexes (ISGF3; E complex) in cytoplasm in 1–2 min; in nucleus in 5 min
1989 Genetic selection system for defective IFN-induced transcription described and first cell mutant selected
IFN-g-dependent promoters (GAS, gamma IFN-activated sequences, and GAF, gamma IFN-activated factor) identified
1989–1991 JAKs 1 and 2 and TYK2 identified
1990 ISGF-3 partially purified; identified subunits 113, 91, 84, 48
1991 Noncomplementing mutant cells unresponsive to both IFN-a and IFN-g described
1992 cDNA clones sequenced later called STAT1 (a and b) and STAT2; RNA for IRF9 completing make up of ISGF3, establishing
STAT family of proteins
First IFN response mutant identified as Tyk2 by molecular complementation
Upon IFN activation by IFN-a STAT1 and STAT2 are tyrosine phosphorylated; STAT1 also tyrosine phosphorylated
after IFN-g treatment
1993–1994 Major signaling events driven by IFN and IL-6 pinpointed by molecular complementation of mutant cells
1994 JAK3 described and sequenced
1994–1995 STAT3, 4, 5A, 5B, and 6 all described and sequenced
1995–1998 Functional and structural domains of STATs described
1996 Drosophila STAT (dSTAT92E) first described; later studied extensively genetically
Mouse genetics identifies physiological functions for all STATs in various specific cells
1997 Negative regulation of pathways initially characterized
1998 First crystal structures of STATs
2000 Initial information that human mutations in JAKs and STATs and persistent activation of STATs cause disease
First posttranslational modifications of STATs in addition to phosphorylations noted (methylation, acetylation, etc.)
2001 Comprehensive gene target sets identified
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studying the induction of specific mRNAs and proteins by IFN
that the pathway was revealed.
Early Recognition of the Importance of IFN: The Darnell
Contribution
For my part, I first learned about interferon from Royce Lockart,
who worked for his PhD degree with Neal Groman at the Univer-
sity of Washington studying virus interference (Lockart and
Groman, 1958). I had joined Harry Eagle’s laboratory in 1956
and was directed by Eagle to use his advances in cell culture
techniques to begin to study the biochemistry of virus infections
in a homogenous population of cultured animal cells. When
Lockart came to the Eagle lab in 1957, he told me about the
interferon papers that were one of the wonders of the world of
virology at the time but were beyond the ability of two neophytes
like us to study.
Royce turned to work on IFN after his postdoctoral time with
Eagle and was hired in the 1960s by E.I. du Pont in Wilmington,
Delaware, to form and lead a group working on animal viruses.
Several scientists in this new group, including a biochemist
named Ernest (Pete) Knight were charged with determining
whether interferon or a fragment of interferon might be devel-
oped as a commercially useful product. In 1961, my lab at MIT
had begun work on cellular (HeLa cell) RNA and had begun the504 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.task of determining how eukaryotic mRNA was formed. Pete
joined us in 1967 after we moved to the Albert Einstein College
of Medicine and worked for a year to learn the primitive tricks
of 1960s RNA biochemistry, knowing that IFN production might
involve dealing with mRNA. Pete showed that the small 5S
ribosomal RNA was not made from pre-rRNA contemporane-
ously with the 28S and 18S rRNAs (Knight and Darnell, 1967).
He also discovered that a 5.8S (we called it 7S) RNAwas synthe-
sized as part of 45S pre-rRNA but remained hydrogen bonded
to 28S RNA during processing (Pene et al., 1968). I kept in touch
with Pete and Royce out of mutual interests and also, by that
time, I was a du Pont consultant. These fortunate contacts
eventually led me and my colleagues to work on IFN.
By 1980 our laboratory, now at Rockefeller University, had
become engrossed in using cDNA libraries from polysomal
mRNA to study transcriptional control of eukaryotic mRNA
production. For the first time, individual members of cDNA
libraries could be used to monitor the rate of synthesis of
mRNA (mRNA precursors) from single eukaryotic genes.
We isolated a series of cDNA clones from rat liver mRNA
and picked out a dozen or so that were abundant in liver and
absent or very scarce in brain, kidney, or spleen (Derman et al.,
1981). By using isolated nuclei to monitor chain elongation by
[32P]UTP incorporation, we showed that liver nuclei gave strong
transcriptional signals for the liver-specific mRNAs, whereas
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Powell et al., 1984). These were among the most convincing
results at the time showing that cell-specific mRNA synthesis
depended, at least as the first event, on cell-specific transcrip-
tional control. This so-called run-on transcription assay with
nuclei was first documented by Ronald Cox in 1976 (Cox,
1976) to represent short, already engaged RNA polymerase II
chain elongation. Furthermore run-on transcription remains the
most precise and straightforwardmeans of determining differen-
tial rates of transcription of individual genes and would prove
invaluable later in studying IFN action.
David Clayton, a Rockefeller University graduate student,
showed that isolated cultured hepatocytes still had most of their
liver-specific mRNA and produced liver-specific proteins 24 hr
after culture but stopped transcribing mRNA precursors at the
normal rates (Clayton and Darnell, 1983; Clayton et al., 1985).
He went one step farther. Thin slices of liver (10 cell diameters)
placed in culture continued to transcribe virtually normally after
24 hr. Hepatocytes are released as free cells for culture by
perfusing the liver with EDTA-containing solution. If David
perfused the liver with the disaggregating solutions but, instead
of splitting the liver capsule to release individual cells, he reper-
fused the liver with serum containing culture medium and Mg2+
and Ca2+ salts, he could now slice the perfused liver without
disaggregation and culture the slices, and liver-specific tran-
scription was maintained. Maintaining cell contact seemed to
be crucial for maintaining specific transcription.
We decided that to make further progress on transcriptional
control, wemust find a simple system in which a known extracel-
lular agent, a protein presumably, could be used to initiate
changes in specific transcription. By this time, Pete Knight and
colleagues had made great progress in purifying IFN-b (one of
a group of so-called leukocyte IFNs that also included many
related IFN-a molecules). Moreover, Knight and a colleague,
Bruce Korant, had shown that IFN-b caused human fibroblasts
to produce new proteins (detected by 2D gel separations of
radioactively labeled proteins) within several hours that were
not present in untreated cells. These proteins were not produced
in the presence of the RNA synthesis inhibitor actinomycin,
although the majority of cell proteins continued to be made nor-
mally (Knight and Korant, 1979).
Pete, his colleagues, and I decided that wewould try to identify
specific mRNAs induced by IFN-b. With IFN-b purified by Knight
and colleagues, Andy Larner in our lab made a cDNA library
from HeLa cells with and without IFN treatment (Larner et al.,
1984). Several cDNAs not present without IFN were indeed
found in the library from the IFN-treated cells. We immediately
tested by run-on analysis and found a large increase (>30-fold)
in the transcriptional rate of these interferon-stimulated genes
(ISGs). Two important points came from these experiments.
The transcriptional activation came very quickly (within 15 min)
and blocking protein synthesis with cycloheximide before IFN
treatment did not affect the transcriptional increase. Thus, the
proteins responsible for the IFN-dependent increase pre-existed
in the cells and presumably were modified somehow to become
active in stimulating transcription.
As related in the accompanying section of this review, George
Stark and Ian Kerr and their colleagues (particularly Richard
Friedman, a Stanford graduate student in the Stark lab), whowere also pursuing the question of IFN induction of genes, did
almost exactly identical experiments (Friedman et al., 1984).
They in fact made larger libraries than we did and consequently
found more IFN-dependent mRNAs than we did. They also
showed by run-on analysis that increased transcription occurred
for one of their seven IFN-dependent cDNAs.
By this time (1986), my lab had had success in identifying
genomic DNA elements in genes expressed mainly in the liver
that bound activating DNA-binding proteins, so-called transcrip-
tional activators. Moreover, we were beginning to succeed in
purifying these proteins and believed, therefore, that we could
clone the genes for several of these liver-enriched transcription
factors. Therefore, the task of solving IFN-dependent gene
activation seemed straightforward—identify and purify the
positive-acting transcription factor(s) driving IFN-responsive
genes. David Levy had the first success on this path, finding
a nucleotide stretch just 50 to the start site of one of the cloned
mRNAs in Andy Larner’s collection that conferred IFN respon-
siveness in a reporter assay (Levy et al., 1986).
Knight and colleagues had purified and partially sequenced
a 15 kD protein (ISG15, IFN-b-stimulated gene 15), made after
IFN treatment of cells, and had obtained a cDNA clone (Blom-
strom et al., 1986). With this clone, Nancy Reich in our lab proved
that ISG15 was indeed transcriptionally controlled by IFN
treatment (Reich et al., 1987). She then cloned the genomic
ISG15 DNA and determined the location of an IFN-responsive
DNA element. When Levy and Reich compared the immediate
50 sequences of the two ISG genes, a highly conserved 25
base pair region was evident 100 nucleotides upstream of
the start site for each of these mRNAs. Mutations within these
‘‘promoters,’’ termed interferon-stimulated response elements
(ISREs), blocked the IFN-dependent reporter responses.
David Levy, Nancy Reich, and several others in our lab, with
these IFN-dependent promoters, began in 1986 the arduous
task of determining whether we might first identify and then
purify a common protein or protein complex that was respon-
sible for the IFN-a and IFN-b transcriptional increase. They
used as a guide the run-on results (Levy et al., 1988). The pro-
tein(s) complex should not be found in uninduced cells, should
be present within minutes after IFN treatment in the nucleus,
and should not require new protein synthesis to be induced.
By this time, workers studying eukaryotic transcription had
adopted a technique developed for bacterial extracts in the lab
of Don Crothers at Yale by which DNA fragments containing
protein-binding DNA regulatory sites could be retarded in
electrophoretic migration through polyacrylamide gels by their
cognate DNA binding regulatory proteins (Fried and Crothers,
1981). Such colloquially termed ‘‘gel-shift’’ experiments worked
for Levy and colleagues with IFN-treated extracts. Several
proteins were detected that bound the IFN-dependent
promoters, the ISRE, but only one was IFN dependent, formed
quickly, and remained during transcriptional increase (Levy
et al., 1988, 1989). The factor was first detected in the cytoplasm
after a 1 or 2 min IFN-b treatment and then accumulated in the
nucleus. The complex appeared to be large because it migrated
through a gel much more slowly than other complexes. Another
protein complex that bound to the ISRE increased with time
after IFN treatment, indicating perhaps that it contained IFN-
dependent proteins but was not likely to be the IFN-dependentImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 505
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christened ISGF3 for interferon-stimulated gene factor 3.
An important fact was uncovered that made purification prac-
tical. Most IFN-b-induced ISGs were not responsive to IFN-g,
which was under study by Thomas Decker and Danny Lew in
our lab (Decker et al., 1989; Lew et al., 1989). But together with
David Levy and Dan Kessler, a graduate student, they found
that prior exposure of HeLa cells to IFN-g enabled a much
more vigorous subsequent IFN-a transcriptional response
(Levy et al., 1990). Additionally, the prior IFN-g treatment greatly
increased the amount of ISGF3, the DNA promoter-binding
complex produced in response to IFN-a and IFN-b. Moreover,
the cytoplasm of the IFN-g-treated HeLa cells contained
a limiting amount of some component of ISGF3 because such
cytoplasm would, when added to cytoplasmic extracts of IFN-
a-treated cells, greatly increase the amount of ISGF3. Thus,
some portion of ISGF3, but not the whole thing, seemed likely
to be an IFN-g-induced protein. The practical import of these
results was that purification was going to be much easier after
IFN-a treatment of HeLa cells that had been pretreated overnight
with IFN-g. And HeLa cells grown in suspension were the only
cells that we could grow in large enough amounts to make
purification an appealing prospect.
Settling on ISFG3 as the target, purification began. X.-Y. Fu,
who came to us from Jim Manley’s lab where nuclear proteins
required for poly(A) addition to pre-mRNA were under study,
began the ISGF3 purification (Fu et al., 1990). The best partially
purified preparations contained ISGF3 concentrated by more
than a hundred fold but were obviously still not pure. However,
a tiny bit produced a robust ISFG3 signal. I suggested to Dan
Kessler, a graduate student who was working with Fu and
others, to try a short cut. Simply use enough of the partially puri-
fied extract to give a whopping ISGF3 binding signal detected
with the 32P-labeled promoter fragment, run the mixture on an
acrylamide gel, identify the ISGF3 band by autoradiography
without drying the gel, cut out the band, elute the proteins, and
run a protein-stained acrylamide gel. Bingo—Dan identified
clearly four proteins, nominally 113, 91, 84, and 48 kDa. The
smallest protein proved to be the HeLa cell protein increased
by prior IFN-g treatment.
Fortunately at this point, Chris Schindler joined the group,
regularized the protein purification, and obtained reproducible
results with specific oligonucleotide (ISRE) affinity chromatog-
raphy demonstrating that, after extensive additional purification,
the 113, 91, 84, and 48 kDa species were the major proteins
remaining and therefore were appropriate targets for sequencing
(Schindler et al., 1992a). He made a preparation from 200 l of
HeLa cells in which the 113, 91, 84, and 48 kDa proteins were
clearly separated after gel electrophoresis. In early 1991, Reudi
Aebersold took the isolated proteins and returned tryptic peptide
sequences to us within a short while. Peptides specific for the
113 kDa and other peptides shared by 91 and 84 kDa showed
that we probably had two isoforms of one protein and one addi-
tional large protein plus one considerably smaller 48 kDa protein.
From sequences specific for 113, 91, and 84 kDa peptides,
oligonucleotide probe libraries were prepared to search cDNA
clones for a match. These standard techniques identified such
clones and sequence analysis proved that the 113 and 91–
84 kDa peptides were likely to be two members of a gene family.506 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.The cDNAs for 91 and 84 kDa showed a differential poly(A)
choice, producing a different 30 exon choice that explained their
difference in size. By using the original peptide sequences
furnished by Aebersold, Schindler prepared antibodies to both
the 91 and 113 kDa proteins. (David Levy in his new lab at
NYU finished off the complete sequencing of the 48 kDa cDNA
[Veals et al., 1992].) With the 91 kDa or the 113 kDa antisera,
Schindler showed that all of the proteins in the 113, 91, 84,
and 48 complex coimmunoprecipitated. Thus, somehow
we had blindly purified a multiprotein complex held together
presumably by protein:protein interactions.
Before we had the complete sequences of the cDNAs, Schin-
dler made another important discovery. Cells treated with a
broad-spectrum serine kinase inhibitor still activated ISGF3.
But staurosporin, which also inhibits tyrosine kinases, com-
pletely blocked IFN-a-dependent induction of ISGF3 (Schindler
et al., 1992b). Based on this result, Schindler with others, partic-
ularly Ke Shuai, a new postdoc, and Vince Prezioso, a graduate
student, then demonstrated with 32P protein labeling and anti-
body precipitation that the vast majority of the 32P label in all
three proteins was in tyrosine, a big surprise. A single identical
tryptic peptide labeled with 32P was found in the 84 and
91 kDa proteins and a different phosphorylated peptide was
present in the 113 kDa protein.
Thomas Decker and Danny Lew (Decker et al., 1991; Lew
et al., 1989) had by this time identified an IFN-g-specific pro-
moter (GAS, gammaIFN-activated site) with a different sequence
from the ISRE and a protein that bound to this promoter (GAF,
gammaIFN-activated factor). Ke Shuai showed that this protein
migrated differently than ISGF3 in a gel. Schindler, Shuai, and
others showed that this protein was precipitated with the anti-
serum against the 91 kDa protein and was phosphorylated.
The single tyrosine phosphorylation site was identified as Y701
in the 91 kDa protein, which could be activated by either IFN-
a or IFN-g (Schindler et al., 1992b; Shuai et al., 1992, 1993).
Together with Kerr and Stark, Shuai showed that one of their
genetically selected defective cell lines (to be described shortly)
could be caused to respond to IFN-g by transfection of the
91 kDa cDNA clone (Shuai et al., 1992, 1993). At this point, we
gave the name STAT1 (signal transducer and activator of
transcription) to this protein and STAT2 to the larger 113 kDa
family member that was found in ISGF3. The designation of the
proteins as STATs came about during a conversation I had
with my late wife, Jane, as we were driving from our home into
New York and I was explaining our new results. She had heard
(patiently) many times about transcription as the copying of
genes into RNA and I was describing our newly isolated proteins
as ‘‘dual function proteins.’’ These proteins received the acti-
vating signal probably at the cell surface that came from a pro-
tein outside the cell and carried the news to the nucleus to
cause—activate—the gene transcription. Thus they were both
signal transducers and then activators of transcription. She
asked whether this was a quick act. I said yes. She said that
STAT meant quick in a hospital and so—signal transducers
and activators of transcription fell out of this conversation.
STATs immediately had a pronounceable and accurate acronym
name.
At this point Kerr, Stark, and I (Darnell et al., 1994) could
describe a plausible tentative conclusion. IFN-a activated two
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that formed a complex with a 48 kDa protein which by that
time had been sequenced in David Levy’s new independent
lab, together with workers in my group. A different receptor-
ligand complex, IFN-g and its cognate receptor, activated
STAT1 but not STAT2, illustrating that differential transcription
factor activation in response to two different ligands led to the
formation of two different transcription complexes.
It is necessary to go back to the earlier experiments of George
Stark and Ian Kerr to connect the JAKs to the STATs and
complete the story.
Analysis of IFN-Dependent Signaling and Connecting
the JAKs to the STATs: The Stark Contribution
I was trained in protein chemistry and enzymology (Stark, 2005)
and gradually became more and more interested in eukaryotic
cell biology and genetics. These two seemingly unrelated
aspects of my research came together when we used PALA,
a transition state analog inhibitor of aspartate transcarbamylase
that we had synthesized, to block de novo pyrimidine nucleotide
biosynthesis in mammalian cells (Kempe et al., 1976). The
resistant mutant clones that emerged provided one of the
first examples of gene amplification, overexpressing CAD,
the three-enzyme protein responsible for the first three steps
of the pyrimidine synthetic pathway (Wahl et al., 1979). This
experience with selection of mutant mammalian cells came in
handy when we were confronted later with the problem of
dissecting IFN-dependent signaling. My interest in interferon
research stems from my long friendship with Ian Kerr. We first
met in 1964, when I was a fresh assistant professor in the
Biochemistry Department at Stanford and Ian was a fresh post-
doctoral fellow there with Bob Lehman. We had little scientific
interaction until the mid-1970s, when Ian’s lab made the
marvelous discovery that 20,50-oligoadenylates (2-5A) were a
vital second messenger in the interferon response, leading to
degradation of RNA in infected cells and thus to inhibition of
viral proliferation (Kerr et al., 1977). In 1977, I was ready for
a sabbatical and imposed on our friendship to request that Ian
put up with me for a year in his MRC lab at Mill Hill in London. I
workedmainly on the 2-5A system, participating in the discovery
with others that the 2-5A synthetases are capable of making, in
addition to classical 2-5A, an interesting series of related oligoa-
denylates, the biological significance of which had long been
mysterious (Cayley and Kerr, 1982; Reid et al., 1984).
Upon returning to Stanford in 1978, my lab continued for
a while to pursue 2-5A biochemistry but gradually became
more and more interested in how cells responded to IFNs. A
breakthrough came through the efforts of Richard Friedman
who, as a graduate student, made a lambda phage library from
IFN-induced mRNAs and screened it with cDNA probes made
from the RNAs of treated or untreated cells. More probe
sequences present in the treated cDNA pools gave stronger
signals from the induced clones, andwewere thus able to isolate
cDNAs corresponding to several strongly induced genes
(Friedman et al., 1984). These were creatively named for the
plate and clone numbers from the screen: 6-16, 1-8, 9-27, etc.
Richard went on to look for homologous sequences in the
promoter regions of several IFN-induced genes, recognizing
the conserved ISRE (Friedman and Stark, 1985), which was laterconfirmed in functional experiments (Porter et al., 1988). This
work was carried out as a distant collaboration with Ian’s lab,
and the attraction of working together more closely, in my
favorite city of London, together with a significant contribution
of midlife crisis, led me to move my lab to the Imperial Cancer
Research Fund in London, where Ian had relocated in 1983.
Our labs were conjoined and we collaborated extensively and
closely during the nine very happy years I spent at ICRF, working
out many details of IFN-dependent signaling.
With the cDNAs and promoter constructs corresponding to
6-16, 1-8, and 9-27, Trevor Dale, a graduate student working
jointly with Ian and myself, carried out a series of experiments
describing the IFN-induced E (for early) factor that bound to
ISREs. In summarizing this work (Dale et al., 1989), we stated
that ‘‘.these results suggest a model for signal transduction in
which latent E factor, located in the cytoplasm, is activated or
released from an inhibitor very rapidly upon binding of IFN-a to
its receptor. Active E factor can then migrate to the nucleus,
where it binds to the IFN-stimulated regulatory elements of
IFN-regulated genes, activating their transcription.’’ ‘‘All’’ that
remained to be done was to define the nature of E factor and
its mechanism of activation. By happy coincidence, Jim Dar-
nell’s lab used their biochemical expertise to great advantage
to isolate E factor (ISGF3) and show that it was comprised of
STAT1, STAT2, and IRF9 (using modern terminology).
We decided to use a genetic approach (see PALA-resistant
cells above). At first, we tried to use the growth-inhibitory effects
of IFN, particularly strong for certain human cell lines, to isolate
resistant mutants, but the clones that we selected were unstable
and thus unsuitable for further work. We then took the bull by
the horns and initiated a dedicated program to use chemical
mutagenesis to create mutant cells in which some protein critical
for IFN-dependent signaling was no longer expressed (Pellegrini
et al., 1989). Many thought this approach was foolhardy. How
could we mutate both alleles of a gene by extensive random
mutagenesis, causing a very large number of changes in the
DNA, and still have viable cells? We tested the idea by deter-
mining the frequency of mutating HPRT, an X-linked single-
copy gene, with ICR 191, an efficient frame-shift mutagen.
Fortunately, a powerful selection technique was available for
cells that did not express HPRT. We found that we could grow
a viable population of mutagenized cells from which HPRT-null
variants could be recovered at a frequency of about 104, so
we could expect to knock out both alleles of a typical gene
with the square of this frequency (about 108) and, if 10 proteins
were essential for IFN-dependent signaling, to recover a mutant
with a frequency of about 107. Thus we forged ahead with
a good sense of how many cells we would need to screen. The
genetic selection utilized a construct in which the 6-16 promoter,
responsive to IFN-a but not IFN-g (Kelly et al., 1985), drove the
expression of guanine phosphoribosyltransferase (GPT), which
activates the prodrug 6-thioguanine to 6-thio-GMP, thereby
killing cells in which GPT is expressed. If the IFN signaling
pathway did not work, no GPT protein would be made in
response to IFN and, voila!, mutant cells that could survive would
be identified. Sandra Pellegrini, a postdoctoral fellow in the lab,
developed this approach. Remarkably, she was able to isolate
our first mutant with approximately the expected frequency
(Pellegrini et al., 1989)! But it was not easy for Sandra to maintainImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 507
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of many months. The first clone (again imaginatively named for
the plate and clone number) was 11,1 (later designated U1A in
a systematic nomenclature). The IFN-regulated GPT construct
allowed for selection of revertant clones that were capable of
growing in hypoxanthine-aminopterin-thymidine (HAT) medium.
Sandra began investigating the 11,1 mutant at ICRF and then,
working in her own new lab at the Pasteur Institute, managed
the difficult job of complementing 11,1 with genomic DNA.
Cosmid clones (large genomic DNA-bearing bacterial clones)
were transfected into 11,1 cells to make them IFN responsive.
After isolating the cosmid responsible, then piecing together
from its sequence a translatable cDNA, we were able to
announce in July 1992 that TYK2 was a required protein in the
IFN pathway (Velazquez et al., 1992).
TYK2 was already known as a member of a new family of
tyrosine kinases for which the substrate(s) had not yet been
uncovered. Andrew Wilks and coworkers in Australia identified
first one (Wilks, 1989) and then a second (Wilks et al., 1991) of
these tyrosine kinases. The molecules had an unusual feature,
namely, both a recognizable kinase domain and a second
domain with great similarity to kinases, originally thought to be
inactive because of amino acid changes at the putative active
site. Because of the two domains, Wilks called the proteins
Janus kinases 1 and 2, by analogy to the two-faced Roman
god Janus. The name has been shortened colloquially to JAKs.
(An apocryphal story is that JAK stands for ‘‘just another
kinase.’’) At almost the same time John Krolewski, in Riccardo
Dalla-Favera’s group, detected and then cloned another JAK
family member, TYK2 (Firmbach-Kraft et al., 1990). These
discoveries of the kinases were just in time.
Thus, the finding by Schindler and others in the Darnell lab
that tyrosine phosphorylation was part of the activation of
ISGF3 was determined to be a JAK-dependent event by Velaz-
quez et al. (1992). With this success and the availability of a set
of mutant cell lines, the floodgates were opened. Given
a complete JAK cDNA (no mean feat at the time for a 6 kb
mRNA), furnished separately by Andrew Wilks and James Ihle,
the Kerr and Stark labs soon showed that IFN-dependent
signaling required both JAK1 and TYK2 to successfully tyrosine
phosphorylate the two substrates STAT1 and STAT2, in
response to IFN-a, and JAK1 and JAK2 to phosphorylate
STAT1 in response to IFN-g (Mu¨ller et al., 1993). It was thought
likely at the outset that noncovalent association of the JAKs
with the IFN receptor (see for example Argetsinger et al., 1993)
and cross phosphorylation of two associated JAKs resulted in
tyrosine phosphorylation of first the kinases and then the
receptor sites to which the SH2 domains of the STATs were
then bound, finally leading to tyrosine phosphorylation of the
STATs.
With the experience of obtaining the first mutant, we realized
that yet more extensive mutagenesis would increase the
frequency of mutation. With the availability of expression
constructs for the JAKs, STATs, IRF9, and receptor subunits,
we were able to obtain and complement a total of eight different
mutant cell lines, each lacking a single protein required for
responses to IFN-a, IFN-g, or both. Although most were isolated
by using a drug-based selection, the mutant g1A, lacking JAK2,
was found by sorting cells that failed to activate expression of508 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.cell surface markers in response to IFN-g (Watling et al., 1993).
These cell lines made possible very productive collaborations,
especially with the Darnell lab, in which many details of the
signaling pathways were worked out. The use of cell lines that
were mutant for the JAKs followed by mutagenesis of STAT
proteins identified the receptor binding sites and the arginine in
the pit of the STAT2 binding domain (reviewed by Stark et al.,
1998, and Levy and Darnell, 2002). So by late 1993, the three
of us, Stark, Kerr, and Darnell, could write a fairly comprehensive
and still largely correct description of the IFN-a- and IFN-g-
dependent activation of the JAK-STAT pathway (Darnell et al.,
1994). During 1994, strong hints arose that other cytokine-
dependent signaling pathways utilized JAKs and STATs. The
mutant cell lines have been made available to more than 500
additional laboratories (still counting), serving as invaluable
reagents to define the roles of the missing proteins in the many
different signaling pathways in which they are now known to
participate.
Completing the JAK-STAT Menagerie
The catalog of the JAKs (only four in number) was completed
more quickly than uncovering the remaining five STATs. During
1994 at least four or five laboratories identified JAK3 (the fourth
and still final JAK to be discovered), which had limited cell
distribution, in contrast to JAK1, JAK2, and TYK2 (Johnston
et al., 1994; Rane and Reddy, 1994; Takahashi and Shirasawa,
1994; Witthuhn et al., 1994). Also early in the examination of
lymphocytic cell lineages it was found that JAK3 mutations
underlay long-recognized lymphocytic disease syndromes.
Rounding out the STAT collection began with a flurry of papers
identifying phosphotyrosine-containing DNA binding factors
that did not react with antisera against STAT1 or STAT2 (Larner
et al., 1993; Ruff-Jamison et al., 1993; Sadowski et al., 1993;
Silvennoinen et al., 1993). Furthermore, the growth factors EGF
and PDGF, as well as other cytokines, including IL-6, IL-3,
IL-5, IL-10, and G-CSF, also activated these phosphotyrosine-
containing DNA binding proteins. Could all these factors be
additional STATs?
The question was solved promptly. Zhong Zhong and Zilong
Wen, two graduate students in the Darnell laboratory, using
a lymphocyte cDNA library obtained from Michel Nussenzweig,
cloned STAT3 and STAT4, establishing in the fall of 1993 by
sequence analysis their membership in the STAT family. They
showed that tyrosine phosphorylation of STAT3 occurred in
response to IL-6 and EGF and, together with Ken Murphy’s
lab, that IL-12 activated STAT4 (Zhong et al., 1994a, 1994b; Ja-
cobson et al., 1995). At virtually the same time other laboratories,
notably Shizura Akira in Tadamistsu Kishimoto’s group (Akira
et al., 1994), also cloned STAT3, known to be activated by IL-6
and called earlier the acute phase response factor. This factor
had been studied intensively by Wegenka et al. (1994), who
recognized that the protein bound to a GAS element. Also, David
Levy and colleagues, later in 1994, identified STAT3 as a relative
of STAT1 (Campbell et al., 1995). Finally, Jim Ihle’s group inde-
pendently cloned STAT4, also in 1994 (Yamamoto et al., 1994).
Other workers in diverse systems around the world were at-
tempting to identify the nature of DNA binding proteins. Bernd
Groner followed the transcriptional response to prolactin and
steroid stimulation of the b-casein gene in mammary gland
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was purified and the gene cloned and sequenced (Wakao et al.,
1994). JimDarnell was sent Bernd’s paper with his colleagues for
review only amonth or two after Zhong andWen had finished the
sequence of STAT3 and STAT4. It was obvious that Groner and
his colleagues had purified and cloned the gene for another
STAT family member. He discarded his referee’s anonymity
and wrote Groner that he had found another family member
and he might consider calling it STAT5. Groner demurred,
sticking with MGF, mammary gland factor. Eventually the world
at large, including Bernd, adopted STAT5. The cast was
completed by Alice Mui and colleagues at the DNAX Research
Institute in California (Mui et al., 1995), who isolated a distinctly
different duplicated gene very similar to STAT5, encoded on
the same chromosome. Groner and Lothar Henninghausen,
also a bit later, independently cloned the STAT5B molecule
(Liu et al., 1995). The two proteins, which became known as
STAT5A and STAT5B, are expressed differently in different
tissues. The seventh and final STAT (still only seven in mammals)
was identified and sequenced at Tularik by J. Hou and U. Schin-
dler and colleagues in the lab directed by Steven McKnight (Hou
et al., 1994). STAT6, as this protein became named, was distrib-
uted mainly in bone marrow-derived cells (mainly lymphocytes).
Thus, in a cloudburst, essentially finished between 1991 and
1994, the cast of JAK-STAT family members and the outlines
of the pathway were complete. Many continuing structural and
functional protein studies and a huge number of physiological
studies on the proteins of the pathway have been accomplished
over the past 17 years (Stark et al., 1998; Levy and Darnell, 2002;
Sehgal et al., 2003). The deep involvement of these proteins in
many normal cellular functions—growth and development and
homeostasis of virtually all tissues, the immunologic response,
and acute primary response to infection and inflammation—are
all critical functions that can go awry or be improperly regulated
in disease. The pathway has become a major target of medical
understanding and potential corrective therapy. Details of these
subjects seem destined to continue to be uncovered, bringing
deeper understanding of disease and, it is widely hoped, rational
therapy for many ailments.
Building on History
A brief review of where this work stood by 1994 in the larger
context of cell signaling seems in order. First, when we began
chasing how IFN stimulated specific gene transcription (in
1984), very little was known about how mammalian cells
changed course in response to extracellular polypeptides. It
was established that transcription rates could be measured by
run-on analysis with cell nuclei and that changes in transcription
rates did occur in response to steroids. Of course, steroids
entered cells and bound to cognate receptors with resulting
increases in specific gene transcription (McKnight and Palmiter,
1979). But no connection between a specific cell surface
receptor and a specific extracellular protein contact that resulted
in targeted gene transcriptional changes had been established.
Two decades of work before the 1980s had identified the
underlying biochemistry that caused fluctuations in internal
‘‘secondmessengers’’—cAMP, diacylgylcerol, and phosphoino-
sitides as well as Ca2+ ions. These changes were joined in the
1970s and 1980s by hundreds of studies on serine and tyrosinephosphorylation cascades, overactivation of which were atten-
dant to oncogenic transformation. By the early 1980s, second
messengers and phosphorylation cascades were invoked as
the agents likely to be responsible for regulating transcription
controlled in response to extracellular signaling proteins (Ber-
ridge, 1987; Bourne and DeFranco, 1990; Gill, 1990; Gilman,
1987; Hunter, 1990).
From the beginning of our interest, it seemed unlikely that the
high degree of specificity of IFN:receptor interaction (indeed of
any extracellular signaling protein and its specific receptor) fol-
lowed by specific gene activation in the nucleus would depend
on the relatively nonspecific fluctuations in second messengers
(Levy and Darnell, 1990). Indeed, this has turned out to be the
case. The tool that linked the JAKs to the STATs, namely cell
lines mutant in different individual genes, proved that the identi-
fied members of the pathway functioned as proposed. The JAK-
STAT pathway results were the first to close the loop—specific
identified and cloned receptors to which specific ligands
attached, activating specific members of an identified and
cloned group of kinases, which in turn activated identified
specific members of a latent cytoplasmic set of transcription
factors that finally, after accumulation in the nucleus, directed
increased transcription of specific genes.
The idea of sets of latent transcription factors responsive to
sets of specific receptors for the purpose of directing transcrip-
tion of specific sets of genes raised the question of how many
such pathways there were. Although there are always surprises
in store, it can be tentatively advanced that there are relatively
few (reviewed by Brivanlou and Darnell, 2002).
NF-kB was the first latent cytoplasmic transcription factor
to be recognized that required for its activation proteolytic
destruction of a protein-bound cytoplasmic inhibitor. But the
cell surface receptor systems that brought about the release
weren’t understood quite so early as the JAKs that respond to
cytokines. Other latent cytoplasmic transcription factors fol-
lowed, including the SMADs and several signaling pathways
first identified in Drosophila. These include Notch, a cell surface
protein, the cleaved internal domain of which furnishes the DNA
binding component of composite transcription factors; the Wnt
pathway, which preserves the b-catenins from destruction,
which in turn serve as transcription factors; the hedgehog
pathway, which preserves the Ci (cubitus interruptus) protein
(called the GLI proteins in mammals) to serve as transcription
factors; and finally the Tubby proteins, which are anchored at
the cell membrane and require release by a lipase to enter the
nucleus and act as transcription factors (Brivanlou and Darnell,
2002). The conclusion can be at least reasonably advanced
that we now know the major pathways that are responsive to
specific protein-protein ligand receptor interactions followed
by induction of specific gene sets.
Posttranslational Modifications Other than
Phosphotyrosine
As research on the STATs has progressed over the years, it
has become clear that these proteins are subject to important
posttranslational modifications in addition to tyrosine phosphor-
ylation. Furthermore, some STATs function as transcription
factors even without tyrosine phosphorylation, and some carry
out important cellular functions independently of transcription.Immunity 36, April 20, 2012 ª2012 Elsevier Inc. 509
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of many facets of JAK-STAT signaling that are still very active
and important areas of ongoing research.
In 1995, phosphorylation of both STAT1 and STAT3 on S727
was shown in cell culture experiments to be necessary, in addi-
tion to tyrosine phosphorylation, for full activation of transcription
in response to IFNs and gp130-linked cytokines such as IL-6,
respectively (Wen et al., 1995). Experiments in mice in which
these serine residues were mutated to alanines extended these
cell culture results (Varinou et al., 2003; Shen et al., 2004).
A different serine residue of STAT1, S708, is phosphorylated in
response to type I IFNs by IKKε, a modification that is needed
for ISGF3 to activate a subset of IFN-stimulated genes (Tenoever
et al., 2007). More recent work from the Maniatis laboratory
(Ng et al., 2011) reveals that S708 phosphorylation inhibits
STAT1 homodimerization but not ISGF3 formation, thus regu-
lating differentially the STAT1-dependent signals that are due
to type I and type II IFNs. Along similar lines, Perwitasari et al.
(2011) show that STAT1 tyrosine phosphorylation is required
for STAT1 S708 phosphorylation and that this modification
leads to expression of the IFIT2 gene, imparting innate immunity
that restricts West Nile virus infection. A JAK- and receptor-
independent mode of STAT activation that also affects immune
function was revealed by the work of Chen et al. (2011). In
many different cells, virus infection triggers STING (also named
MITA or ERIS) to recruit STAT6 to the endoplasmic reticulum,
leading to phosphorylation of S407 and Y641. Homodimers
of tyrosine- and serine-phosphorylated STAT6 then activate
specific target genes in the nucleus that mediate immune cell
homing. Another example of JAK-independent STAT phosphor-
ylation is provided by recent work of Gao et al. (2012) showing
that STAT3 is phosphorylated in nuclei by dimeric pyruvate
kinase M2, helping to promote cell proliferation in response to
alterations in glucose metabolism.
STAT3 is dimethylated on K140 by SET9 in response to IL6
and demethylated by LSD1 (Yang et al., 2010). These enzymes,
initially discovered based on their ability to modify histones,
also modify wild-type STAT3 bound to the SOCS3 promoter
but not the S727A mutant, showing that prior S727 phosphory-
lation is required for methylation, possibly by helping to recruit
SET9 to tyrosine-phosphorylated STAT3 dimers bound to the
promoter. Lysine methylation has not yet been demonstrated
for other STATs, but has emerged as an important posttransla-
tional modification for p53 and NF-kB (Stark et al., 2011). The
methylation of STAT1 on R31 was reported by Mowen et al.
(2001) to have important consequences for the function of
tyrosine-phosphorylated STAT1 dimers, but this work has
been controversial (Meissner et al., 2004; Komyod et al.,
2005). However, two recent studies are supportive of R31
methylation. Iwasaki et al. (2010) show that arginine N-methyl-
transferase 2 links STAT3 methylation to the ability of leptin,
an activator of STAT3 tyrosine phosphorylation, to regulate
energy balance. In a fascinating study, Elizabeth Sampaio and
colleagues (personal communication) have analyzed human
autosomal-dominant gain-of-function STAT1 mutations that
predispose to severe disseminated fungal infections. The
mutated amino acid residues are far apart in the linear
sequence of STAT1 but cluster near R31 in the three-dimen-
sional structure. The mutations decrease the ability of R31 to510 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.be methylated, thus increasing the binding to STAT1 of
PIAS1, which catalyzes SUMOylation of lysine residues (Shuai,
2006; Tahk et al., 2007). SUMOylation of STAT1 on K703 by
PIAS1 inhibits its activation (Ungureanu et al., 2005) and also
inhibits the formation of STAT1 nuclear paracrystalline arrays,
which makes tyrosine-phosphorylated STAT1 more susceptible
to inactivation by nuclear phosphatases (Droescher et al.,
2011). SUMOylation is not known to occur in any other STAT,
and therefore these are not prevented from forming paracrystal-
line arrays. Tyrosine-phosphorylated STATs in these arrays
are protected from inactivating nuclear phosphatases, thus
prolonging their activation.
Although Yuan et al. (2005) indicated that the reversible
acetylation of STAT3 on K685 by the acetyltransferase p300
was essential for its cytokine-stimulated function, this work has
been criticized (O’Shea et al., 2005). Several recent reports
have shown that acetylation of K685 is important for functions
of STAT3 that are independent of tyrosine phosphorylation,
namely for the activation of STAT3 mediated by nuclear translo-
cation of CD44 (Lee et al., 2009), for downregulating the ability
of STAT3 to inhibit gluconeogenesis (Nie et al., 2009), and for
the STAT3-dependent effects of IL-22 in keratinocytes (Sestito
et al., 2011).
Functions of Unphosphorylated STATs
In the absence of tyrosine phosphorylation, STATs have at least
three distinctly different functions, as transcription factors or
modifiers of transcription factors, as effectors of mitochondrial
function, and as effectors of chromatin structure. As reviewed
recently (Cheon et al., 2011), the STAT1 gene responds to
IFNs and the STAT3 gene responds to IL-6 (and related cyto-
kines) through conventional GAS or ISRE elements in the
respective promoters, leading to large increases in the concen-
trations of each protein after cytokine treatment. Although the
initial responses to IFNs and IL-6 that are due to tyrosine phos-
phorylation are downregulated rapidly, through a variety of
mechanisms but especially through the activities of the SOCS
proteins, the responses to increased concentrations of U-STATs
persist for many days. The STAT1 and STAT3 responses are
distinct: the STAT1 gene does not respond to IL-6 and the
STAT3 gene does not respond to IFNs, and completely different
sets of genes are regulated to the two different U-STATs. The
genes regulated by U-STAT3 are also distinct from those
induced by tyrosine-phosphorylated STAT3, and several of
them, such as MRAS and MET, have well-described roles in
oncogenesis, thus potentially contributing to the major role of
STAT3 in cancer (Yang et al., 2005). Some genes are regulated
by U-STAT3 through a complex transcription factor formed in
combination with NF-kB, in which NF-kB provides the DNA-
binding and transactivation domains and STAT3 is responsible
for nuclear translocation (Yang et al., 2007). U-STAT1 prolongs
the expression of a subset of IFN-induced genes (Cheon and
Stark, 2009), in combination with U-STAT2 and IRF9, the other
two components of ISGF3, which are also induced in response
to IFNs (Stark, data not shown). Thus, there are three forms of
ISGF3: YP2-ISGF3 is formed when both STAT1 and STAT2 are
tyrosine phosphorylated in response to type I IFNs; YP1-
ISGF3 is formed when only STAT1 is tyrosine phosphorylated
in response to IFN-g (Morrow et al., 2011); and U-ISGF3 is
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proteins are increased in response to IFNs (Stark, data not
shown). Many of the U-ISGF3-induced proteins have well-
known antiviral or immune-regulatory functions (Cheon and
Stark, 2009), and their continued expression, long after the initial
response to IFN has been downregulated, serves to prolong
resistance to virus infection for many days. Some of the U-
ISGF3-induced proteins are also able to mediate resistance to
DNA damage in the many cancers in which U-ISGF3 is overex-
pressed (Weichselbaum et al., 2008).
Two examples reveal additional unique transcription-related
functions of U-STATs. Yue et al. (2010) show that angiotensin
II-dependent signaling induces increased expression of U-
STAT3 through an unknown mechanism, contributing to angio-
tensin II-induced cardiac hypertrophy, and Testoni et al. (2011)
show that U-STAT2 is constitutively bound to many IFN-acti-
vated promoters before IFN treatment, contributing to their basal
regulation.
Gough et al. (2011) have reviewed recent work showing
important roles for STAT3 outside the nucleus, including in
mitochondria, where STAT3 has been reported to support
RAS-dependent oncogenic transformation (Gough et al.,
2009), and to participate in cellular respiration (Wegrzyn et al.,
2009). More recently, Szczepanek et al. (2011) have shown
that mitochondrial STAT3 protects against stress-induced
changes in the electron transport chain that result in the
generation of reactive oxygen species. U-STAT5 now joins
the party, as Lee et al. (2012) have shown that both U-STAT5A
and U-STAT5B are associated with the Golgi apparatus and
rough endoplasmic reticulum in vascular cells, with dramatic
effects on the stability of these organelles after STAT5 knock-
down.
There is only one STAT in Drosophila, and Yan et al. (2011)
provide additional evidence for their earlier conclusion that U-
dSTAT promotes heterochromatin stability through its interac-
tion with heterochromatin protein 1 (HP1). Genetic manipulation
to reduce the levels of either U-dSTAT or HP1 leads to reduced
levels of heterochromatin and consequently to increased
susceptibility to DNA damage and defects in chromosomal
compaction and segregation during mitosis. The work of Chris-
tova et al. (2007) in human cells reveals that chromatin carrying
the entire major histocompatibility complex (MHC) locus loops
out in response to treatment with IFN-g and that this phenom-
enon is dependent upon the tyrosine phosphorylation of
STAT1. A plausible connection between the two observations
is that depletion of the pool of U-STAT1, rather than formation
of tyrosine-phosphorylated STAT1, might be responsible for
the observed changes in the organization of the MHC locus. A
recent example of negative regulation of gene expression in
response to STAT activation is that STAT5 tetramers, formed in
response to IL-7, bind to the Igk intronic enhancer, recruiting
the histone lysine methyl transferase EZH2, which in turn trime-
thylates H3K27, creating a repressive mark that blocks Igk
expression (Mandal et al., 2011).
Each month brings new publications describing unexpected
additional functions for the JAKs and STATs. These ubiquitous
and amazingly adaptable ancient proteins have become linked
to a wide variety of seemingly disparate functions over evolu-
tionary time. What will the next 20 years bring?REFERENCES
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